Benzinga | Jun 15, 2021 07:54AM EDT

Oppenheimer Maintains Outperform on ResMed, Raises Price Target to $270

Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $240 to $270.